A Phase II study to evaluate ABC294640 as a radioprotectant to prevent mucositis and radiation enhancer in cancer patients undergoing radiotherapy

Trial Profile

A Phase II study to evaluate ABC294640 as a radioprotectant to prevent mucositis and radiation enhancer in cancer patients undergoing radiotherapy

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs ABC 294640 (Primary)
  • Indications Cancer; Head and neck cancer; Radiation-induced abnormalities
  • Focus Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 01 Mar 2016 According to a RedHill Biopharma media release, this trial is expected to be initiated in second half of 2016.
    • 06 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top